Skip to content
Triangle logo TriangleGet started
← Study library

NCT01159574 · REGISTRY CONDITION SEARCH

Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2019-06-11

This study is intended to investigate the combination of the combination of dexamethasone (Decadron®), Clarithromycin (Biaxin®), and pomalidomide (CC-4047®) \[ClaPd\] in multiple myeloma patients who have relapsed or refractory disease who have failed prior treatment with lenalidomide when used alone or in combination with corticosteroids. Primary endpoint will be response rate to treatment. Secondary endpoints will include toxicity of the combination, time to maximum response, and time to disease progression

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Response Rate

→

outcome · POSTED

Time to Maximum Response, Expressed as Number of Cycles of Treatment to Maximum Response

→

outcome · POSTED

Time to Disease Progression (Progression Free Survival)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Subject must voluntarily sign and understand written informed consent. * Age \> 18 years at the time of signing the consent form. * Histologically confirmed MM * Relapsed or refractory myeloma, progression of disease either after prior therapy or lack of response to currently used therapy. * Relapsed or progressive disease after at least 3 prior therapeutic treatments or regimens for multiple myeloma. * Must have been previously treated with lenalidomide and has been determined to be refractory, resistant, or relapsed. * Measurable disease as defined by \> 0.5 g/dL serum monoclonal protein, \>0.1 g/dL serum free light chains, \>0.2 g/24 hrs urinary M-protein excretion, and/or measurable plasmacytoma(s). * Karnofsky performance status ≥70% (\>60% if due to bony involvement of myeloma * Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to and again within 24 hours of prescribing lenalidomide and thalidomide (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 4 weeks before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with females of child bearing potential even if they have had a successful vasectomy. See Appendix V: Pomalidomide Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods. †A female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). * Able to take aspirin daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin). † * 1ife expectancy ≥ 3 months * Subjects must meet the following laboratory parameters: Absolute neutrophil count (ANC) ≥750 cells/mm3 (1.0 x 109/L) Platelets count ≥ 50,000/mm3 (75 x 109/L) Serum SGOT/AST ≤ 2.0 x upper limits of normal Serum SGPT/ALT \<3.0 x upper limits of normal (ULN) Serum creatinine ≤ 2.5 x upper limits of normal Serum total bilirubin ≤ 1.5 x upper limits of normal Exclusion Criteria: * Patients with non-secretory MM (no measurable monoclonal protein, free light chains, and/or M-spike in blood or urine). * Prior history of other malignancies (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless disease free for ≥ 5 years. * Myocardial infarction within 6 months prior to enrollment, or NYHA(New York Hospital Association) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia or active conduction system abnormalities. * Known HIV infection * Known hepatitis B or hepatitis C infection. * Active viral or bacterial infections or any coexisting medical problem that would significantly increase the risks of this treatment program. * Any coexisting medical problem or laboratory evaluation that, in the treating physician's or principal investigator's opinion, makes the patient unsuitable to participate in this clinical trial. * Known hypersensitivity to thalidomide or lenalidomide. * History of thromboembolic event within the past 6 months prior to enrollment. * Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form. * Pregnant or breast feeding females. * Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study. * Use of any other experimental drug or therapy within 14 days of baseline. * Known hypersensitivity to thalidomide or lenalidomide. * The development of erythema nodorum if characterized by a desquamating rash while taking thalidomide, CC-4047 or similar drugs. * Any prior use of CC-4047. * Concurrent use of other anti-cancer agents or treatments.
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    ClaPd therapy: Dexamethasone (40mg ) will be given on days 1, 8, 15, 22 of a 28-day cycle. Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle. Pomalidomide will be given 4mg daily for days 1-21 of each 28 day cycle. Dosing will be in the morning at approximately the same time each day.
    intervention Names
    1. Drug: dexamethasone
    2. Drug: clarithromycin
    3. Drug: Pomalidomide
    label
    all patients
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. all patients
    description
    40mg will be given on days 1, 8, 15, 22 of a 28-day cycle
    name
    dexamethasone
    other Names
    1. Decadron
    type
    DRUG
  2. arm Group Labels
    1. all patients
    description
    orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle
    name
    clarithromycin
    other Names
    1. Biaxin
    type
    DRUG
  3. arm Group Labels
    1. all patients
    description
    orally 4mg daily for days 1-21 of each 28 day cycle
    name
    Pomalidomide
    other Names
    1. CC-4047
    type
    DRUG
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
121
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Best response rate was recorded for all patients, using the IMWG criteria.
    measure
    Overall Response Rate
    time Frame
    from baseline to cycle with maximum response, which was achieved on average after 2 cycles
secondary Outcomes
  1. measure
    Time to Maximum Response, Expressed as Number of Cycles of Treatment to Maximum Response
    time Frame
    From baseline to cycle of maximum response, which occurred on average after 2 cycles; 1 cycle = 28 days
  2. measure
    Time to Disease Progression (Progression Free Survival)
    time Frame
    From start of treatment, to date of disease progression
Full study description
brief Summary
This study is intended to investigate the combination of the combination of dexamethasone (Decadron®), Clarithromycin (Biaxin®), and pomalidomide (CC-4047®) \[ClaPd\] in multiple myeloma patients who have relapsed or refractory disease who have failed prior treatment with lenalidomide when used alone or in combination with corticosteroids. Primary endpoint will be response rate to treatment. Secondary endpoints will include toxicity of the combination, time to maximum response, and time to disease progression
detailed Description
This phase II study is a treatment program for patients with relapsed or refractory multiple myeloma who have had prior treatment with lenalidomide. Up to 54 patients will be enrolled. Patients who sign informed consent form and fulfill all eligibility criteria will be enrolled. ClaPd therapy: Dexamethasone (40mg ) on days 1, 8, 15, 22 of a 28-day cycle. Clarithromycin given orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle. Pomalidomide will be given 4mg daily for days 1-21 of each 28 day cycle. Serial clinic visits and laboratory measurements will be performed to monitor for treatment response. Those patients who demonstrate progression of disease at any point during ClaPd therapy will be taken off study. At the end of every cycle (which may coincide with day 1 of the new cycle), response and toxicity will be evaluated. During cycle 1, patients will have labwork done weekly (CBC with differential and blood electrolytes). All patients will remain on study until disease progression or side effects become excessive. Patients who achieve a stable plateau may be taken off study if eligible to proceed to high dose chemotherapy and autologous stem cell transplantation.
Source references
references
  1. citation
    Mark TM, Forsberg PA, Rossi AC, Pearse RN, Pekle KA, Perry A, Boyer A, Tegnestam L, Jayabalan D, Coleman M, Niesvizky R. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma. Blood Adv. 2019 Feb 26;3(4):603-611. doi: 10.1182/bloodadvances.2018028027.
    pmid
    30792190
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-0c51887334fa70269689
      requested nct id
      NCT01159574
      primary nct id
      NCT01159574
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      cdf19f051cf68bdfd04e79777acb672203250d88ebf35e3400197d8e88ab494e
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-0c51887334fa70269689
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01159574
      occurrences
      1. context exact
        NCT01159574
        end
        11
        exact text
        NCT01159574
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/239/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      bca4d2c864532397f9327cb4685a63d3e2f63db1a8b878070885611f4e39452a

    Preserved source evidence · Not medical advice